References
- Silberstein SD, Kori SH, Aurora SK et al. Efficacy and tolerability of MAP0004, a novel inhaled therapy, in treating acute migraine. Presented at: The International Headache Congress (IHC), Philadelphia, PA, USA, 10–13 September 2009.
- Goldstein J, Smith TR, Pugach N, Griesser J, Sebree T, Pierce M. A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache 52(9), 1402–1410 (2012).
- Djupesland PG, Docekal P; Czech Migraine Investigators Group. Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: a randomised, placebo-controlled study. Cephalalgia 30(8), 933–942 (2010).
- Hoffmann J, Goadsby PJ. New agents for acute treatment of migraine: CGRP receptor antagonists, iNOS inhibitors. Curr. Treat. Options Neurol. 14(1), 50–59 (2012).
- Han TH, Blanchard RL, Palcza J et al. Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults. J. Clin. Pharmacol. 50(12), 1367–1376 (2010).
- Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci. 24(8), 450–455 (2001).
- Wieseler-Frank J, Maier SF, Watkins LR. Glial activation and pathological pain. Neurochem. Int. 45(2–3), 389–395 (2004).
- Takeda M, Takahashi M, Matsumoto S. Contribution of the activation of satellite glia in sensory ganglia to pathological pain. Neurosci. Biobehav. Rev. 33(6), 784–792 (2009).
- Hanani M. Satellite glial cells in sensory ganglia: from form to function. Brain Res. Brain Res. Rev. 48(3), 457–476 (2005).
- Thalakoti S, Patil VV, Damodaram S et al. Neuron–glia signaling in trigeminal ganglion: implications for migraine pathology. Headache 47(7), 1008–1023 (2007).
- Capuano A, De Corato A, Lisi L, Tringali G, Navarra P, Dello Russo C. Proinflammatory-activated trigeminal satellite cells promote neuronal sensitization: relevance for migraine pathology. Mol. Pain 5, 43 (2009).
- Ledeboer A, Hutchinson MR, Watkins LR, Johnson KW. Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin. Investig. Drugs 16(7), 935–950 (2007).
- Ledeboer A, Liu T, Shumilla JA et al. The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biol. 2(4), 279–291 (2006).
- Schwedt TJ, Dodick DW, Hentz J, Trentman TL, Zimmerman RS. Occipital nerve stimulation for chronic headache–long-term safety and efficacy. Cephalalgia 27(2), 153–157 (2007).
- Matharu MS, Bartsch T, Ward N, Frackowiak RS, Weiner R, Goadsby PJ. Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain 127(Pt 1), 220–230 (2004).
- Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ; ONSTIM Investigators. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 31(3), 271–285 (2011).
- Reed KL, Black SB, Banta CJ 2nd, Will KR. Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: initial experience. Cephalalgia 30(3), 260–271 (2010).
- Tepper SJ, Rezai A, Narouze S, Steiner C, Mohajer P, Ansarinia M. Acute treatment of intractable migraine with sphenopalatine ganglion electrical stimulation. Headache 49(7), 983–989 (2009).
- Lainez M, Jensen R, May A et al. Pathway CH-1 Study: sphenopalatine ganglion (SPG) stimulation for acute treatment of chronic cluster Headache (CCH) – initial experience (S36.002). Neurology 78(Meeting Abstracts 1), S36.002 (2012).
Website
- Merck Updates Status of Clinical Development Programs for Investigational CGRP Receptor Antagonist Treatments for Acute Migraine – FierceBiotech. www.fiercebiotech.com/press-releases/merck-updates-status-clinical-development-programs-investigational-cgrp-receptor-anta#ixzz2AP1GceC3 (Accessed 26 October 2012)